Skip to content
To the full analysis

Intco Medical Technology Stock: Valuation and P/E

300677.SZ
$7.23Closing price of 20 Nov 2026MEQIRI Score 45 out of 100

Intco Medical Technology trades at a P/E of 108.9 (Healthcare sector median 30.9, own median of recent years 18.1).

Daily figure as of 20 Nov 2026

P/E
108.9
earnings collapsed, on expected earnings 12.2
P/S
2.5
P/B
1.68
PEG
2.5

P/E on Expected Earnings

The forward P/E of 12.9 divides the price by the earnings per share that 3 analysts expect on average for the next twelve months: $0.59. The twelve months are made up pro rata of the estimates for fiscal 2026 and 2027. The P/E of 108.9, by contrast, uses reported earnings for the last twelve months.

12.9
P/E on fiscal 2026
17.9
on estimated fiscal 2026 earnings ($0.40 per share)
P/E on fiscal 2027
11.7
on estimated fiscal 2027 earnings ($0.62 per share)

Analysts mostly estimate adjusted earnings, excluding amortization of acquisitions and other one-off items. The estimates change all the time; they are no promise and no price target.

Against Its Own Valuation History

Each fiscal year is shown with its P/E on the year-end date, using the price at the time. From 2017 to 2025 the P/E at fiscal year end ranged from 4.2 (2021) to 40.3 (2023).

P/E
108.9
Median of prior years
18.1
Reading
pricier than usual

P/E at Each Fiscal Year End

Figures as a table
YearP/E
201728.6
201815.1
201918.1
20207.7
20214.2
202221.2
202340.3
202411.2
202524.6

P/E of Industry Peers

StockP/EOwn median
Asahi Intecc32.354.7
Teleflex77.637.7
Gan & Lee Pharmaceuticals.31.642.4
Merit Medical Systems31.856.4
Intco Medical Technology108.918.1
ICU Medical73.350.2
Stevanato Group28.337.3
Envista Holdings6.027.6
SCHOTT Pharma24.631.0

The eight peers closest in market value, largest first. Trailing twelve-month P/E as of 20 Nov 2026, loss makers have none.

Data and Required Disclosures

  • ; time horizon around 12 months
  • Rated Weak since 7 Nov 2026; valuation signal Fairly valued since 20 Nov 2026
  • Price: closing price of 20 Nov 2026
  • Amounts in US dollars at the ECB reference rate of 19 Nov 2026 ($1 = CN¥6.6667)
  • Data from Financial Modeling Prep (FMP) based on the company's reports, latest fiscal year 2025. MEQIRI calculates the score and fair value itself every night.
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.